4 hours ago
1
dem10/iStock via Getty Images
- Praxis Precision Medicines (NASDAQ:PRAX) said that the U.S. FDA has given breakthrough therapy status to Relutrigine, a treatment for certain types of developmental and seizure disorders linked to SCN2A and SCN8A genes.
- The EMBOLD cohort 2 main study, which is evaluating Relutrigine, is expected to provide key results in the first half of 2026, followed by a submission for marketing approval.
English (US) ·